First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.
about
Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5Comparative Evaluation of Three Commercially Available Methodologies for Hepatitis C Virus GenotypingPolymorphism in the Human Major Histocompatibility Complex and Early Viral Decline during Treatment of Chronic Hepatitis CBio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitisModelling hepatitis C virus kinetics during treatment with pegylated interferon α-2b: errors in the estimation of viral kinetic parametersBenefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapyTreatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingPredicting the probable outcome of treatment in HCV patients.A perspective on modelling hepatitis C virus infection.Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patientsHepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.Review article: predicting response in hepatitis C virus therapy.Viral kinetics in the treatment of chronic hepatitis C.Hepatitis C Viral Kinetics in Special PopulationsSingle nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.Early viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient.Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C.Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment.Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy.The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.First-phase parameters in hepatitis C viral kinetics.Authors' reply: first-phase parameters in hepatitis C viral kinetics.First phase hepatitis c viral kinetics in previous nonresponders patients.Modeling HCV kinetics under therapy using PK and PD information
P2860
Q27473038-0CE946AD-38A9-442F-B2CB-651EB2AC45D2Q27477505-4D5BD14C-C745-477A-9D72-BBAAC1C7E621Q27487771-1862D969-A7EF-4048-9C73-EF5D1CFD2586Q27488200-92CCCC6D-9A85-43A7-A72A-9C4E4B21A1D6Q27488824-2F8CC877-9347-4EC5-9921-0F1D1A410A32Q33592250-32F28510-6A52-4BE4-9AAC-E5B9B9AE427BQ33899320-0ECAF2CD-99AE-414E-94EB-C230FA1555D2Q34409039-3DEE8047-C8A6-4C35-B50D-B3CFE238A839Q34759489-F2B19E42-63FB-4F5E-B9FF-BDCE1E9B2AEFQ34788754-061C7F6E-055D-42FD-A580-76D0FACF1A29Q35610571-1057DECF-A9B6-49ED-8EDC-DA049A833416Q36346012-3F3A1EAC-A071-4C7A-9A9C-CE0F9CD8650AQ36447562-3979C763-DDEA-4462-93F3-815BACCADF13Q36562168-786C07FA-18C7-4C70-9571-BF15452582CDQ37060801-816C755D-AB2C-4838-9417-ACCFEAACA039Q37449527-650EDD8B-F88F-4F41-9572-E4EAA1DB77F8Q38678972-9D24B751-129D-41AB-B682-D73833887AE7Q41392572-10558630-3A8F-43BF-AAA3-689FFB6DEEEBQ41687110-93E5CD3A-61BA-4D40-AE31-117ABCE46835Q42218328-4E5633CA-10D2-45BA-A919-CD6088E8319AQ42725944-8DDE80CD-62A2-4632-AE63-66FEB8FB9920Q42979490-21A32043-D9DE-4198-8EBB-B534D2EC41A0Q42981009-6B2C4BBE-A302-4D85-BD4F-B65FE898F0C8Q43039934-07D66121-4CF8-4F3A-A0F0-7BC612FDA4B3Q43040998-15CFF38A-85DC-45D4-A455-9EAF6C9138C9Q43042198-19EAD45D-FED3-45CD-BEB1-C57F7867520DQ56935271-06D11CBF-D651-47FB-A974-D52D7C69372F
P2860
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
First phase viral kinetic para ...... he second phase viral decline.
@en
First phase viral kinetic para ...... he second phase viral decline.
@nl
type
label
First phase viral kinetic para ...... he second phase viral decline.
@en
First phase viral kinetic para ...... he second phase viral decline.
@nl
prefLabel
First phase viral kinetic para ...... he second phase viral decline.
@en
First phase viral kinetic para ...... he second phase viral decline.
@nl
P2093
P2860
P1476
First phase viral kinetic para ...... he second phase viral decline.
@en
P2093
Avidan U Neumann
Jennifer E Layden
Jennifer Poulakos
Rachel S Levy-Drummer
Thomas J Layden
P2860
P304
P356
10.1046/J.1365-2893.2002.00377.X
P577
2002-09-01T00:00:00Z